...AmpliPhi acquired from Novolytics assets that include bacteriophage-related IP, bacteriophage libraries, formulation and regulatory information and...
...Staphylococcus aureus. AmpliPhi declined to provide financial terms, and Novolytics did not respond to inquiries. Novolytics Ltd....